Review and prospect of neoadjuvant chemoradiotherapy combined with immunotherapy in locally advanced rec-tal cancer
10.16139/j.1007-9610.2024.03.07
- VernacularTitle:局部进展期直肠癌新辅助放化疗联合免疫治疗的回顾和展望
- Author:
Yaqi WANG
1
;
Fan XIA
;
Zhen ZHANG
Author Information
1. 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系,上海市放射肿瘤学重点实验室,上海市放射治疗临床医学研究中心,上海 200032
- Keywords:
Locally advanced rectal cancer(LARC);
Neoadjuvant chemoradiotherapy;
Immunotherapy;
Complete response;
Organ preservation
- From:
Journal of Surgery Concepts & Practice
2024;29(3):220-229
- CountryChina
- Language:Chinese
-
Abstract:
For locally advanced rectal cancer(LARC),the standard treatment of neoadjuvant chemoradiotherapy(nCRT)followed by total mesorectal excision(TME)leaded to limited tumor regression grade and organ preservation rate,and didn't decrease the rate of distant metastasis.Radiotherapy can promote the immune response and has good synergistic effect with immunotherapy,which is likely to overcome the treatment difficulty of the microsatellite stable(MSS)colorectal cancer.Recently,multiple clinical trials are ongoing in terms of the combination of nCRT and immunotherapy in LARC.Most of them have achieved promising complete response rates,providing new treatment options for preservation of organ functions in mid-low MSS LARC.Large-scale randomized controlled trials are needed in the future to validate these findings and explore the benefit of organ preservation and long-term survival.In addition,studies are still needed on the optimal combination patterns of radiotherapy and immunotherapy and the precise efficacy evaluation,etc.
